Wednesday, August 29, 2007

Presidio Pharmaceuticals Gets $26M

San Francisco-based Presidio Pharmaceuticals said this morning that it has raised $26M in a Series B financing. The round was led by Panorama Capital, and also included Baker Brothers Investments, Bay City Capital, Ventures West Capital, Nexus Medical Partners, Sagamore Bioventures, George Rathmann Fund and Peninsula Overview Partners. Presidio Pharmaceuticals is developing pharmaceuticals based on small molecules, targeted at the treatment of HIV-1, HCV, and other chronic viral infections. Dr. Srinivas Akkaraju of Panorama Capital, Dr. Felix Baker of Baker Bros. Advisors, Dr. Daniel Perez of Bay City Capital, and Kenneth Galbraith of Ventures West have joined the board as part of the funding. More information »